UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with Flagship Pioneering, a biotech company based in Cambridge, Massachusetts, known for its role as a bioplatform for innovation across a diverse portfolio of over 40 companies. The collaboration will see an initial joint funding of up to USD 150 million by GSK and Flagship, with the objective of identifying the most promising concepts and research targets from within Flagship’s extensive network.
The partnership aims to develop up to 10 novel medicines or vaccines, with GSK having the exclusive option to further develop each candidate. Under the agreement, Flagship and its bioplatform companies stand to receive up to USD 720 million in upfront payments, development, and commercial milestones from GSK for each acquired program, in addition to preclinical funding and tiered royalties.
Flagship Pioneering, launched in 2000, has a track record of establishing over 100 scientific ventures and has deployed over USD 3.8 billion in capital across its companies, attracting more than USD 27 billion in investments from external institutions. The firm’s current portfolio includes notable names such as Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.- Flcube.com
